Therapeutic Drug Monitoring for Personalized Uveitis Care
Official title: Therapeutic Drug Monitoring in Uveitis for Long-term Individualized Patient Care
Funded at Emory University · NIH-11273888 · Data updated 2026-11-12
A patient-friendly look at using blood tests to tailor adalimumab therapy for non-infectious uveitis to keep vision safer over the long term.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $667,544 |
| NIH project number | 1R01EY038199-01 |
| Project ID | NIH-11273888 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with non-infectious uveitis who are treated with adalimumab and are experiencing or at risk of suboptimal response.
✕Less likely to help
Patients not receiving adalimumab or those with strictly non-TNF-α related disease may see limited direct benefit.
What this research studies
Non-infectious uveitis can threaten vision and often requires ongoing immune-suppressing treatment. This project uses blood tests to measure adalimumab levels and anti-drug antibodies to find the right dose range and reduce loss of response. It will follow patients across multiple sites to understand how drug levels relate to active eye inflammation and why some people stop responding. The study also investigates factors that predict treatment failure and how TNF-α levels change over time to guide care. The goal is to help doctors personalize therapy so patients maintain better disease control with fewer side effects.
Why it matters
Potential benefit: If successful, patients could receive more precise dosing of adalimumab, leading to better control of uveitis and fewer vision-threatening flares.
How similar studies have gone: Prior work shows that tracking drug levels can help optimize anti-TNF therapies, but this study aims to define a specific concentration target for NIU.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Shantha, Jessica — Emory University
- Study coordinator: Shantha, Jessica
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.